Literature DB >> 24857066

Liver-directed therapies: surgical approaches, alone and in combination with other interventions.

Gaya Spolverato1, Timothy M Pawlik1.   

Abstract

When feasible, surgical resection is typically the preferred therapeutic option in patients with both primary and secondary hepatic malignancies. Improved patient selection, preoperative management, and advances in perioperative care have had a considerable effect on short-term and long-term outcomes following hepatic resection. Parenchymal transection of the liver can be performed using many different techniques such as digitoclasia, clamp crushing, vessel sealing system, harmonic scalpel, water-jet, Cavitron Ultrasonic Surgical Aspirator, or radiofrequency dissecting sealer. At the time of surgery, one of the main factors that influences postoperative morbidity and mortality is blood loss. Different techniques are used to decrease blood loss, such as the Pringle maneuver, selective ligation of the right, left, or smaller branches of the portal system; extrahepatic dissection; isolation; and transection of the hepatic artery and portal vein and the total vascular exclusion. Liver resection is on occasion accompanied by a concomitant procedure. Given that colorectal liver metastasis is a common indication for liver resection, colon resection is one of the more common concurrent procedures, but also surgical management of other disease in the lung or pancreas may sometimes be indicated. A subset of patients with primary or secondary liver malignancies may also require the addition of an ablative therapy to treat the extent of disease in the liver. Moreover, occasionally, hepatic resection takes place following intra-arterial therapy administration to the liver. Although many of these patients may benefit from surgical therapy, a multidisciplinary team approach remains critical.

Entities:  

Mesh:

Year:  2014        PMID: 24857066     DOI: 10.14694/EdBook_AM.2014.34.101

Source DB:  PubMed          Journal:  Am Soc Clin Oncol Educ Book        ISSN: 1548-8748


  5 in total

1.  Updates and Critical Insights on Glissonian Approach in Liver Surgery.

Authors:  Demetrios Moris; Amir A Rahnemai-Azar; Diamantis I Tsilimigras; Ioannis Ntanasis-Stathopoulos; Hugo P Marques; Eleftherios Spartalis; Evangelos Felekouras; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2017-11-03       Impact factor: 3.452

2.  Intraoperative surgical margin re-resection for colorectal liver metastasis: is it worth the effort?

Authors:  Georgios A Margonis; Gaya Spolverato; Yuhree Kim; Aslam Ejaz; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2014-12-02       Impact factor: 3.452

3.  Neuroendocrine Liver Metastasis: Prognostic Implications of Primary Tumor Site on Patients Undergoing Curative Intent Liver Surgery.

Authors:  Gaya Spolverato; Fabio Bagante; Luca Aldrighetti; George Poultsides; Todd W Bauer; Ryan C Field; Hugo P Marques; Matthew Weiss; Shishir K Maithel; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2017-07-25       Impact factor: 3.452

4.  Impact of Delta Hemoglobin on Provider Transfusion Practices and Post-operative Morbidity Among Patients Undergoing Liver and Pancreatic Surgery.

Authors:  Gaya Spolverato; Fabio Bagante; Matthew Weiss; Jin He; Christopher L Wolfgang; Fabian Johnston; Martin A Makary; Will Yang; Steven M Frank; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2016-09-30       Impact factor: 3.452

5.  A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis.

Authors:  Javier Rodriguez; Eduardo Castañón; Jose Luis Perez-Gracia; Inmaculada Rodriguez; Antonio Viudez; Carlos Alfaro; Carmen Oñate; Guiomar Perez; Fernando Rotellar; Susana Inogés; Ascensión López-Diaz de Cerio; Leyre Resano; Mariano Ponz-Sarvise; Maria E Rodriguez-Ruiz; Ana Chopitea; Ruth Vera; Ignacio Melero
Journal:  J Immunother Cancer       Date:  2018-09-29       Impact factor: 13.751

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.